Alkermes announced Monday it would acquire Rodin Therapeutics, a Boston-based biotech developing drugs intended to change brain cells’ synapses, for up to $950 million. The deal is worth $100 million upfront, but could be worth up to $850 million more based on milestone payments. 

The deal gives Alkermes another potential path to growth following a handful of disappointments in its research pipeline and the 2018 refusal of the Food and Drug Administration to even consider one of its drug candidates, for treatment-resistant depression.

Rodin was founded in 2013 by Atlas Ventures. other backers include GV, the venture arm of Google; Hatteras Venture Partners; and Third Point Ventures.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy